The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Adult Malignant Glioma Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Glioma is a broad category of brain and spinal cord tumors that come from glial cells brain cells that support nerve cells.The symptoms, prognosis, and treatment of a glioma depend on the person’s age, the exact type of tumor, and the location of the tumor within the brain.
The global Adult Malignant Glioma Therapeutics market size is expected to reach US$ 1901.4 million by 2029, growing at a CAGR of 5.2% from 2023 to 2029. The market is mainly driven by the significant applications of Adult Malignant Glioma Therapeutics in various end use industries. The expanding demands from the Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers and Others, are propelling Adult Malignant Glioma Therapeutics market. Glioblastoma Multiforme, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anaplastic Astrocytoma segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Adult Malignant Glioma Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Adult Malignant Glioma Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Adult Malignant Glioma Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Adult Malignant Glioma Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Adult Malignant Glioma Therapeutics covered in this report include Merck, Hoffmann-La Roche, Arbor Pharmaceuticals, Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Sun Pharmaceutical and Teva Pharmaceutical, etc.
The global Adult Malignant Glioma Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Hoffmann-La Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceutical
Teva Pharmaceutical
Novocure
Eli Lilly
AstraZeneca
Novartis AG
Bayer
Emcure Pharmaceuticals
Global Adult Malignant Glioma Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Adult Malignant Glioma Therapeutics market, Segment by Type:
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Other
Global Adult Malignant Glioma Therapeutics market, by Application
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Adult Malignant Glioma Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Glioma is a broad category of brain and spinal cord tumors that come from glial cells brain cells that support nerve cells.The symptoms, prognosis, and treatment of a glioma depend on the person’s age, the exact type of tumor, and the location of the tumor within the brain.
The global Adult Malignant Glioma Therapeutics market size is expected to reach US$ 1901.4 million by 2029, growing at a CAGR of 5.2% from 2023 to 2029. The market is mainly driven by the significant applications of Adult Malignant Glioma Therapeutics in various end use industries. The expanding demands from the Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers and Others, are propelling Adult Malignant Glioma Therapeutics market. Glioblastoma Multiforme, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anaplastic Astrocytoma segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Adult Malignant Glioma Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Adult Malignant Glioma Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Adult Malignant Glioma Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Adult Malignant Glioma Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Adult Malignant Glioma Therapeutics covered in this report include Merck, Hoffmann-La Roche, Arbor Pharmaceuticals, Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Sun Pharmaceutical and Teva Pharmaceutical, etc.
The global Adult Malignant Glioma Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Hoffmann-La Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceutical
Teva Pharmaceutical
Novocure
Eli Lilly
AstraZeneca
Novartis AG
Bayer
Emcure Pharmaceuticals
Global Adult Malignant Glioma Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Adult Malignant Glioma Therapeutics market, Segment by Type:
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Other
Global Adult Malignant Glioma Therapeutics market, by Application
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Adult Malignant Glioma Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Adult Malignant Glioma Therapeutics
1.1 Adult Malignant Glioma Therapeutics Market Overview
1.1.1 Adult Malignant Glioma Therapeutics Product Scope
1.1.2 Adult Malignant Glioma Therapeutics Market Status and Outlook
1.2 Global Adult Malignant Glioma Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Adult Malignant Glioma Therapeutics Market Size by Region (2018-2029)
1.4 Global Adult Malignant Glioma Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Adult Malignant Glioma Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Adult Malignant Glioma Therapeutics Market Size (2018-2029)
1.6.1 North America Adult Malignant Glioma Therapeutics Market Size (2018-2029)
1.6.2 Europe Adult Malignant Glioma Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size (2018-2029)
1.6.4 Latin America Adult Malignant Glioma Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size (2018-2029)
2 Adult Malignant Glioma Therapeutics Market by Type
2.1 Introduction
2.1.1 Glioblastoma Multiforme
2.1.2 Anaplastic Astrocytoma
2.1.3 Anaplastic Oligodendroglioma
2.1.4 Other
2.2 Global Adult Malignant Glioma Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Adult Malignant Glioma Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Adult Malignant Glioma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Adult Malignant Glioma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Adult Malignant Glioma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Adult Malignant Glioma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Adult Malignant Glioma Therapeutics Revenue Breakdown by Type (2018-2029)
3 Adult Malignant Glioma Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Specialty Clinics
3.1.3 Cancer and Radiation Therapy Centers
3.1.4 Others
3.2 Global Adult Malignant Glioma Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Adult Malignant Glioma Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Adult Malignant Glioma Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Adult Malignant Glioma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Adult Malignant Glioma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Adult Malignant Glioma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Adult Malignant Glioma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Adult Malignant Glioma Therapeutics Revenue Breakdown by Application (2018-2029)
4 Adult Malignant Glioma Therapeutics Competition Analysis by Players
4.1 Global Adult Malignant Glioma Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Adult Malignant Glioma Therapeutics as of 2022)
4.3 Date of Key Players Enter into Adult Malignant Glioma Therapeutics Market
4.4 Global Top Players Adult Malignant Glioma Therapeutics Headquarters and Area Served
4.5 Key Players Adult Malignant Glioma Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Adult Malignant Glioma Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Merck
5.1.1 Merck Profile
5.1.2 Merck Main Business
5.1.3 Merck Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.1.4 Merck Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Merck Recent Developments
5.2 Hoffmann-La Roche
5.2.1 Hoffmann-La Roche Profile
5.2.2 Hoffmann-La Roche Main Business
5.2.3 Hoffmann-La Roche Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.2.4 Hoffmann-La Roche Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Hoffmann-La Roche Recent Developments
5.3 Arbor Pharmaceuticals
5.3.1 Arbor Pharmaceuticals Profile
5.3.2 Arbor Pharmaceuticals Main Business
5.3.3 Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.3.4 Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Pfizer Recent Developments
5.4 Pfizer
5.4.1 Pfizer Profile
5.4.2 Pfizer Main Business
5.4.3 Pfizer Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.4.4 Pfizer Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Pfizer Recent Developments
5.5 AbbVie
5.5.1 AbbVie Profile
5.5.2 AbbVie Main Business
5.5.3 AbbVie Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.5.4 AbbVie Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 AbbVie Recent Developments
5.6 Amgen
5.6.1 Amgen Profile
5.6.2 Amgen Main Business
5.6.3 Amgen Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.6.4 Amgen Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Amgen Recent Developments
5.7 Bristol-Myers Squibb
5.7.1 Bristol-Myers Squibb Profile
5.7.2 Bristol-Myers Squibb Main Business
5.7.3 Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.7.4 Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Bristol-Myers Squibb Recent Developments
5.8 Sun Pharmaceutical
5.8.1 Sun Pharmaceutical Profile
5.8.2 Sun Pharmaceutical Main Business
5.8.3 Sun Pharmaceutical Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.8.4 Sun Pharmaceutical Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Sun Pharmaceutical Recent Developments
5.9 Teva Pharmaceutical
5.9.1 Teva Pharmaceutical Profile
5.9.2 Teva Pharmaceutical Main Business
5.9.3 Teva Pharmaceutical Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.9.4 Teva Pharmaceutical Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Teva Pharmaceutical Recent Developments
5.10 Novocure
5.10.1 Novocure Profile
5.10.2 Novocure Main Business
5.10.3 Novocure Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.10.4 Novocure Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Novocure Recent Developments
5.11 Eli Lilly
5.11.1 Eli Lilly Profile
5.11.2 Eli Lilly Main Business
5.11.3 Eli Lilly Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.11.4 Eli Lilly Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Eli Lilly Recent Developments
5.12 AstraZeneca
5.12.1 AstraZeneca Profile
5.12.2 AstraZeneca Main Business
5.12.3 AstraZeneca Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.12.4 AstraZeneca Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 AstraZeneca Recent Developments
5.13 Novartis AG
5.13.1 Novartis AG Profile
5.13.2 Novartis AG Main Business
5.13.3 Novartis AG Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.13.4 Novartis AG Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Novartis AG Recent Developments
5.14 Bayer
5.14.1 Bayer Profile
5.14.2 Bayer Main Business
5.14.3 Bayer Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.14.4 Bayer Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 Bayer Recent Developments
5.15 Emcure Pharmaceuticals
5.15.1 Emcure Pharmaceuticals Profile
5.15.2 Emcure Pharmaceuticals Main Business
5.15.3 Emcure Pharmaceuticals Adult Malignant Glioma Therapeutics Products, Services and Solutions
5.15.4 Emcure Pharmaceuticals Adult Malignant Glioma Therapeutics Revenue (US$ Million) & (2018-2023)
5.15.5 Emcure Pharmaceuticals Recent Developments
6 North America
6.1 North America Adult Malignant Glioma Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Adult Malignant Glioma Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Adult Malignant Glioma Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Adult Malignant Glioma Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Adult Malignant Glioma Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Adult Malignant Glioma Therapeutics Market Dynamics
11.1 Adult Malignant Glioma Therapeutics Industry Trends
11.2 Adult Malignant Glioma Therapeutics Market Drivers
11.3 Adult Malignant Glioma Therapeutics Market Challenges
11.4 Adult Malignant Glioma Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
